MedPage Today, a property of Everyday Health, Inc. (NYSE: EVDY), and CollabRx, Inc. (NASDAQ: CLRX) said they have introduced a new physician resource, CancerRx, an IOS application designed to help oncologists and pathologists navigate the complex landscape of oncology therapeutic options.
“The introduction of CancerRx expands MedPage Today´s relationship with CollabRx to provide our professional readers and all those who treat cancer with a powerful decision support tool that will directly impact cancer treatment planning on an individual patient level,” said Ben Wolin, CEO of Everyday Health.
The initial focus of the app will be the molecular aspects of laboratory testing and therapy development in cancer, the foundation of “precision” oncology in which each patient´s cancer treatment plan is individually tailored to reflect the genetic profile of their tumor. Precision oncology is the most promising area of cancer drug development and CancerRx will broadly enable and empower oncologists to use this approach in treating their patients.
The CancerRx app offers expert-vetted guidance of treatment options for lung cancer, melanoma, metastatic breast cancer and colourectal cancer based on tumor genetic profiles, stage, and histology in addition to other important clinical parameters, as relevant, such as treatment history. All are developed in close collaboration with CollabRx´s expert advisory network, which is composed of over 75 leading physicians, scientists, and researchers from the nation´s most prestigious academic and medical institutions as well as thought leaders spanning diverse backgrounds.
CollabRx is a recognized leader in cloud-based expert systems to inform healthcare decision-making. More information may be obtained at http://www.collabrx.com.
MedPage Today, a property of Everyday Health, provides health care professionals with broad, timely and relevant news coverage that directly affects their practices. Everyday Health is a provider of digital health and wellness solutions.